AINEWS
A $50 Million Argument About What a Human Body Is For
Inside the inaugural Enhanced Games, where athletes were encouraged to take performance enhancing drugs, the line between medical progress and bodily rules got harder to defend.
Inside the inaugural Enhanced Games, where athletes were encouraged to take performance enhancing drugs, the line between medical progress and bodily rules got harder to defend.
The first Enhanced Games ran on May 24 inside a $50 million arena built in a Las Vegas casino parking lot. The athletes competing there were openly encouraged, under the event's own rules, to take performance-enhancing drugs. The point was not secrecy. The point was the opposite.
According to MIT Technology Review's on-the-ground feature on the inaugural event, the competition was framed as a libertarian thought experiment: a test of what athletes could do if the only substances they had to avoid were the ones a regulator had not approved. The event's protocol reportedly permits only FDA-approved drugs, and the athletes individually choose what to take. Some chose nothing, and won anyway. Triple Olympic medalist Hunter Armstrong took the men's backstroke without enhancements. Fred Kerley won the men's 100-meter sprint unenhanced. Their presence is part of the story. The field was open, and the rules did not force anyone toward a syringe.
The event is also a commercial bet. The Enhanced Games brand is tied to a supplement and peptides line: injectable peptides marketed for cellular energy and skin elasticity, plus "Stronger" and "Longer" powders aimed at the longevity market. The argument is that the same logic that lets an athlete use a hormone under medical supervision should let a 50-year-old buy injectable peptides at a checkout, and eventually let a 70-year-old reverse a piece of the aging process. The athletics is the front of the store. The longevity commerce is the back.
The "FDA-approved drugs only" framing is the company's, and it does most of the work for the event's legitimacy. Approved is not the same as safe under chronic enhancement use, or in the combinations a motivated athlete might assemble. The framing also shifts the harder question from the event to the regulator, who is not in the room. MIT Technology Review's reporting from the event also documents the self-selection reality, including at least one high-profile participant who initially said he had used no PEDs and later walked that back. The protocol is permissive. The honesty about who used what is the part still being negotiated.
As The Download, MIT Technology Review's weekday newsletter, framed the cultural question on June 10: were the supporters right, and what does this mean for everyone else? Both questions are live, and neither has a clean answer. The bioethical critique is real. Drugs that are safe in short medical doses are not necessarily safe in chronic enhancement doses, and the people most exposed to that risk are the ones with the least leverage to refuse. The fairness critique is also real. An event open to anyone willing to inject creates a different kind of pressure than a league that bans the practice, and that pressure does not stop at the event's edge.
The cultural tension the event exposes is older than the arena. Medical progress has been pushing past the line we draw at "enhancement" for decades, in fertility treatment, in ADHD prescriptions, in hormone replacement therapy. The rules of the body that line enforces are collective. The technology that erodes them is increasingly individual. The Enhanced Games did not invent that tension. They just put it on a track and timed it.
The counterargument is also real, and harder than it looks. Most of what we treat as "natural" athletic performance is already the product of training, equipment, nutrition, and recovery technologies that did not exist a generation ago. The line between treatment and enhancement is being redrawn whether or not Las Vegas hosts a second edition.
What to watch is whether the consumer peptides and supplements commerce follows the athletics into the mainstream, and whether regulators respond to the consumer side of the bet, not the arena side. The arena is the spectacle. The market is the experiment.